BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 22309416)

  • 1. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
    Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
    Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
    Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
    Zhang X; Wang Z; Fan J; Liu G; Peng Z
    Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV; Saldaña-Cruz AM; Pérez-Guerrero EE; Morán-Moguel MC; Contreras-Haro B; López-de La Mora DA; Dávalos-Rodríguez IP; Marín-Medina A; Rivera-Cameras A; Balderas-Peña LA; Gómez-Ramos JJ; Cortés-Sanabria L; Salazar-Páramo M
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
    Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
    J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.
    Li D; Zhu JY; Gao J; Wang X; Lou YQ; Zhang GL
    Clin Chim Acta; 2007 Aug; 383(1-2):133-9. PubMed ID: 17568575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
    Gijsen V; Mital S; van Schaik RH; Soldin OP; Soldin SJ; van der Heiden IP; Nulman I; Koren G; de Wildt SN
    J Heart Lung Transplant; 2011 Dec; 30(12):1352-9. PubMed ID: 21930396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
    Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
    Miao LY; Huang CR; Hou JQ; Qian MY
    Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.